Transcriptomic data-mining approach for identifying potential pharmacogenetic candidates in antiepileptic drug response Letter to the Editor Sir, Antiepileptic drug (AED) therapy is known to be associated with significantly high rates of adverse reactions and ineffective seizure control in a considerable proportion of epileptic patients. [1] Currently in its infancy, [2, 3] pharmacogenomics of AED response therefore constitutes a priority area in the fi eld of personalized medicine. Although interest in the genetic association of adverse drug reactions and efficacy is gradually increasing, hypothesis-free genome-wide association study (GWAS) approaches in epilepsy have not become a reality yet. [2, 3] Candidate-based association approaches will thus remain the mainstay in the area of epilepsy genetics and AED pharmacogenetics in the immediate future. Success of such approaches will however depend much on the criteria used for selecting the candidate genes. Identifying promising candidate genes will not only enhance the chances of success in candidate-based association studies but will also assist in the analysis of Four reports on NaVP were identifi ed as relevant in the context of brain or neuronal function -rat brain, 30day treatment [4] (gene list, pers comm.); mouse brain, 7-day treatment; [5] cultured rat cortical neurons, 12-h treatment; [6] human neuroblastoma cells, 6-and 72-h treatments. [7] These diverse studies reported differentially expressed genes with insignifi cant overlaps. The genes were therefore pooled together for downstream analysis, total up-and down-regulated genes being 817 and 360, in that order. The Functional Annotation Tool in DAVID [8, 9] with the total number of NaVP regulated genes in these processes being 298. Although small numbers precluded a statistical test for signifi cance of this overlap, the trend for enrichment of pharmacogenetic candidates in differentially expressed genes is obvious considering the total number of genes in the human genome. Given the above, my analysis, in particular, supports the candidacy of HLA-B and HSPA1A in AED pharmacogenetics. In general, it supports the usefulness of transcriptomic data in pharmacogenetic association studies.
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